← Eichor
Study identifier: NCT06266832 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma

Condition: Rectal Adenocarcinoma  ·  Sponsor: Sir Run Run Shaw Hospital

PhasePhase 2
Planned participants30
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

To evaluate the efficacy, safety and organ retention rate of short-course radiation combined with Adebrelimab and CAPEOX neoadjuvant therapy in patients with MSS/pMMR ultra low rectal adenocarcinoma.

This description comes directly from the study's public registry record.

Talk to the study team

sheng dai, MD&PhD  ·  13575472669  ·  daimd@zju.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Sir Run Run Shaw Hospital, Zhejiang University School of MedicineHangzhou, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06266832